Oblon Spivak Blog

May 15, 2013

This is a test blog.

February 1, 2013

Third party submissions in the past have not been frequently used in the U.S. or elsewhere.  In Europe, reports are that less than 1% of applications have had observations filed.  Despite the low use, reports from Europe do indicate that over 50% of examiners made use of the observations in prosecution, with over 14% finding that the observations resulted in a major reduction in scope or refusal. 

Recently, changes in U.S. law (discussed below) are intended to encourage...

August 16, 2012

A 2-1 split panel of the Federal Circuit issued its decision today in the closely-watched Myriad case, Association for Molecular Pathology v. Myriad Genetics, Inc., __ F.3d __ (Fed. Cir. 2012) (Lourie, J.).

Background of the Case

Myriad originated in the District Court of the Southern District of New York when a coalition of groups and individuals brought a declaratory judgment action against Myriad...

July 27, 2012

In Ex Parte Ransquin, the Board reversed the Examiner’s obviousness rejection noting that the Examiner’s “continued reference” in his Answer to what the prior art discloses, evidenced “a fundamental misunderstanding by the Examiner of the difference between what references teach or disclose and what a proposed combination of references would have suggested to a person of ordinary skill in the art.” Ex Parte Ransquin, No. 2010-012450 (B.P.A.I. June 25, 2012). Since the...

July 23, 2012

In Ex parte Potts (Case No. 2011-004700, in Application Serial No. 11/690,745, decision issued July 17, 2012), the Board rejected as unpatentable subject matter a claimed method for predicting the outcome of a clinical treatment based on measured correlations between treatments and responses, because the claims at issue sought only to patent a “law of nature.”

A.     In its recent decision of Mayo Collaborative Servs. v. Prometheus Labs., Inc. the...